Novo Nordisk's stock rises as Ozempic beat analysts' expectations in sales
In its outlook for 2025, Novo Nordisk has predicted 'continued periodic supply constraints and related drug shortage ...
Novo doubles down on next-gen weight loss therapy despite early setback
With its Q4 2024 results on Wednesday, Novo Nordisk (NVO) announced a new Phase 3 trial to test its highly-anticipated weight loss therapy, CagriSema, after a December readout failed to meet investors ...
ENDPOINTS NEWS42m
No­vo Nordisk is feel­ing the com­pe­ti­tion from com­pound­ed GLP-1s, ex­ec says
Many Americans have flocked to cheaper, compounded versions of GLP-1 weight loss drugs in lieu of brand-name treatments. That ...
Why Novo Nordisk Stock Is Soaring Today
Shares of Novo Nordisk (NYSE: NVO) were moving higher on Wednesday. The company's stock gained 4.9% as of 1:50 p.m. ET, but ...
ThePrint58m
Wall Street mixed, Treasury yields slide amid mixed earnings, data
Wall Street struggled for direction and benchmark Treasury yields slid on Wednesday as disappointing earnings and mixed ...